[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368300-105":59,"doc-detail-368300-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","cpa4-overexpression-correlates-with-poor-prognosis-and-tumor-progression-in-endometrial-cancer","CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer","","Rising incidence and mortality of endometrial cancer worldwide drive the need for better biomarkers and diagnostic strategies. This study evaluates CPA4, previously implicated in cancer development but not yet linked to endometrial cancer. CPA4 mRNA expression was analyzed using TCGA and GEO, then validated in 116 clinical samples with immunohistochemistry. Functional assays used Ishikawa and Hec-1-A cell lines, while bioinformatics included correlation analysis, GO, KEGG, GSEA, and survival analyses. CPA4 is significantly overexpressed, associated with tumor progression and poor prognosis. Knockdown of CPA4 suppresses tumor growth and spread, and Kaplan–Meier and Cox regression support its prognostic relevance. A nomogram prediction model shows high accuracy, highlighting CPA4 as a clinically useful biomarker.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cpa4-overexpression-correlates-with-poor-prognosis-and-tumor-progression-in-endometrial-cancer/368300/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cpa4-overexpression-correlates-with-poor-prognosis-and-tumor-progression-in-endometrial-cancer/368300.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main focus of this study?","Question",{"text":113,"@type":114},"The study investigates whether CPA4 overexpression is associated with prognosis and tumor progression in endometrial cancer, and whether CPA4 could serve as a biomarker.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was CPA4 expression measured and validated?",{"text":118,"@type":114},"CPA4 mRNA expression was analyzed using TCGA and GEO datasets, and validated using immunohistochemistry on 116 endometrial cancer clinical samples.",{"name":120,"@type":111,"acceptedAnswer":121},"What functional effects does CPA4 have in endometrial cancer cells?",{"text":122,"@type":114},"Reducing CPA4 in Ishikawa and Hec-1-A cell lines inhibited tumor growth and spread, supporting CPA4’s role in tumor progression.",{"name":124,"@type":111,"acceptedAnswer":125},"How does the study assess prognostic value and build clinical prediction?",{"text":126,"@type":114},"Survival analyses including Kaplan–Meier plots and Cox regression confirm CPA4’s prognostic significance, and a nomogram model was developed for prognostic predictions with high accuracy.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},368300,1790220610,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","He etal. European Journal  \nEuropean Journal of Medical Research (2025) 30:174  \n[https://doi.org/10.1186/s40001-025-02293-0](https://doi.org/10.1186/s40001-025-02293-0 of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-025-02293-0 of Medical Research)  \n RESEARCH Open Access  \nCPA4 overexpression correlates  \nwith poor prognosis and tumor progression in endometrial cancer  \nKang He1†, Jingying Zheng2†, Tingyu Zhang1†, Hao Lv1, Kai Wang1, Zeyu Wang1, Longyun Wang1, Shan Wu3* and Lijing Zhao1*  \nAbstract  \nBackground The rise in endometrial cancer rates globally calls for advanced diagnostic methods and new biomarkers. CPA4, known for its role in cancer development, has not yet been studied in relation to endometrial cancer, making it a promising research avenue.  \nMethods We analyzed CPA4’s mRNA expression using data from TCGA and GEO databases and validated these findings with 116 clinical samples through immunohistochemical analysis. The Ishikawa and Hec-1-A cell lines were used to examine CPA4’s functionality. In addition, we conducted correlation analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and survival analysis to understand CPA4’s role in endometrial cancer prognosis. A nomogram model was developed for clinical prognostic predictions. Results CPA4 is significantly overexpressed in endometrial cancer, correlating with tumor progression and poor prognosis. Overexpression is linked to crucial functions, such as mitosis and cell cycle. Reducing CPA4 in cell lines inhibited tumor growth and spread. Kaplan–Meier plots and Cox regression analysis confirmed CPA4’s significance in prognosis, with our predictive model showing high accuracy.  \nConclusions CPA4 emerges as a vital biomarker for diagnosing and prognosing endometrial cancer, present  \ning a novel pathway for research and clinical application. The study highlights its potential as a clinical tool, paving the way for improved patient management and treatment strategies in endometrial cancer.  \nKeywords Endometrial cancer, Bioinformatics, CPA4, Prognosis, Biomarkers  \n†Kang He, Jingying Zheng and Tingyu Zhang are contributed equally.  \n*Correspondence:  \nShan Wu [wsgood1994@163.com](wsgood1994@163.com)[ ](wsgood1994@163.com)Lijing Zhao [zhao_lj@jlu.edu.cn](zhao_lj@jlu.edu.cn)  \n1 Department of Rehabilitation, School of Nursing, Jilin University, Changchun 130021, China  \n2 The Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130041, Jilin, China  \n3 Department of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China  \nIntroduction  \nEndometrial cancer, the most common gynecological tumor, accounts for at least 400,000 female deaths annually [1, 2]. In contrast to other gynecological cancers, endometrial cancer is witnessing a rising trend in incidence and mortality rates globally, with an alarming shift towards younger ages [3, 4]. While there are several types of endometrial cancer, the majority of cases are diagnosed early. However, high-grade variants showa tendency to recur and have poor prognoses [5, 6]. Current detection largely relies on symptom presentation, a method with low specificity and no dedicated screening  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated ot","cbCaihfpvrhAlWmj","https://ap.wps.com/l/cbCaihfpvrhAlWmj","pdf",12075093,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Epidemiology and clinical need\n## Rationale for CPA4","[{\"question\":\"What is the main focus of this study?\",\"answer\":\"The study investigates whether CPA4 overexpression is associated with prognosis and tumor progression in endometrial cancer, and whether CPA4 could serve as a biomarker.\"},{\"question\":\"How was CPA4 expression measured and validated?\",\"answer\":\"CPA4 mRNA expression was analyzed using TCGA and GEO datasets, and validated using immunohistochemistry on 116 endometrial cancer clinical samples.\"},{\"question\":\"What functional effects does CPA4 have in endometrial cancer cells?\",\"answer\":\"Reducing CPA4 in Ishikawa and Hec-1-A cell lines inhibited tumor growth and spread, supporting CPA4’s role in tumor progression.\"},{\"question\":\"How does the study assess prognostic value and build clinical prediction?\",\"answer\":\"Survival analyses including Kaplan–Meier plots and Cox regression confirm CPA4’s prognostic significance, and a nomogram model was developed for prognostic predictions with high accuracy.\"}]","CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer | PDF",1790176123,53,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ac12523fd8a95c11e02599f33b7a1c4.webp",983,1305,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8145e3bc29e7f0bfd2ef1527d82160a6.webp",982,1304,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faa0a6a18646e445ec2f171fbdea5ad8.webp",981,1303,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9c9adcafdbf6fd011158cd08247b086.webp",980,1301]